Table 2 Anatomo-clinical and therapeutic characteristics of breast cancer group
From: Transcutaneous canine breast cancer detection in Tunisia: a pilot study
Characteristics (n = 100) |  |
Mean age (years) | 50.17 ± 8.25 |
Number of patients (%) | |
Clinical T stage | |
 T0-Tis | 4 (4) |
 T1 | 19 (19) |
 T2 | 27 (27) |
 T3 | 16 (16) |
 T4 | 34 (34) |
 T4a | 3 (3) |
 T4b | 15 (15) |
 T4c | 6 (6) |
 T4d | 10 (10) |
Clinical lymph nodes N stage | |
 N0 | 47 (47) |
 N1 | 33 (33) |
 N2 | 16 (16) |
 N3 | 4 (4) |
Mammography American college of radiology (ACR) classification | |
 0 | 0(0) |
 1 | 0 (0) |
 2 | 0 (0) |
 3 | 2(2) |
 4 | 33(33) |
 5 | 64 (64) |
 Non specified | 1 (1) |
Molecular subtypes | |
 Triple negative | 16.2 (16.2) |
 Luminal A | 14.1 (14.1) |
 Luminal B HER2 negative | 38.4 (38.4) |
 Luminal B HER2 positive | 25.3 (25.3) |
 HER2 overexpression | 6.1 (6.1) |
Timing between testing and chemotherapy | |
 Before starting chemotherapy courses | 53 (53) |
 During chemotherapy courses | 39 (39) |
 After completion of chemotherapy courses | 8 (8) |
Testing for de novo breast cancer or local relapse | |
 De novo | 91 (91) |
 Local relapse | 9 (9) |